daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Understanding Drug Imbursement Price Cuts in China

Asian Healthcare Spend as a Percentage of GDP – the Laggards

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

<ul>
<li>A high disease burden, high demand for chronic treatment, and an ageing population makes China an excellent opportunity for an established pharma company.</li>
<li>A transition period following the inclusion of four large drugs in the NDRL creates an opportunity following a big de-rating.</li>
<li>With 1/3 of the market cap in cash, a healthy payout ratio, and a FPE of under 8, CMS is one of the bargain beneficiaries in the Chinese healthcare space.</li>
</ul>


A high disease burden, high demand for chronic treatment, and an ageing population makes China an excellent opportunity for an established pharma company.
A transition period following the inclusion of four large drugs in the NDRL creates an opportunity following a big de-rating.
With 1/3 of the market cap in cash, a healthy payout ratio, and a FPE of under 8, CMS is one of the bargain beneficiaries in the Chinese healthcare space.


China Medical System (CMS, 867 HK) – A Cheap Play on China’s Pending Health Care Crisis